Regenerative Cell Therapy Business Addressing Unmet Medical Needs
First written in FY2017. 11 of 13 entries say "Restated". Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1RestatedAnnual report
「Against this backdrop, our Group (hereinafter referring to the two companies, our company and SanBio, Inc. (Oakland, California, USA)) has pursued research and development aimed at commercializing SB623, our Group’s proprietary cell therapy, primarily for central nervous system diseases with high unmet medical needs.」
The policy of pursuing research and development aimed at commercializing SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2026-H1RestatedAnnual report
「Against this backdrop, our Group has pursued research and development aimed at commercializing SB623, our proprietary cell therapy, primarily for central nervous system diseases with high unmet medical needs.」
The policy of pursuing research and development aimed at commercializing SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2024-Q3RestatedAnnual report
「Against this backdrop, the Group advanced research and development with the aim of commercialising its proprietary regenerative cell therapy SB623, primarily targeting central nervous system disorders with high unmet medical needs.」
The basic policy of pursuing value creation through SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2024-Q2RestatedAnnual report
「Against this backdrop, the Group advanced research and development with the aim of commercialising its proprietary regenerative cell therapy SB623, primarily targeting central nervous system disorders with high unmet medical needs.」
The policy of pursuing value creation through SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2024-Q1RestatedAnnual report
「Against this backdrop, the Group advanced research and development with the aim of commercialising its proprietary regenerative cell therapy SB623, primarily targeting central nervous system disorders with high unmet medical needs.」
The policy of pursuing value creation through regenerative medicine and the commercialization of SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2023RestatedAnnual report
「Our Group conducts research and development and manufactures regenerative cell therapies. With the corporate mission of “creating value for patients and other stakeholders through the development of regenerative medicine,” we are pursuing the goal of becoming a global leader in regenerative medicine and are engaged in the research and development of regenerative cell therapies.」
The basic policies of creating value for stakeholders through regenerative medicine, pursuing global leadership, and improving patients’ quality of life through early commercialization have been reaffirmed. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group advanced research and development with the aim of commercialising its proprietary regenerative cell therapy SB623, primarily targeting central nervous system disorders with high unmet medical needs.」
The policy of pursuing value creation through SB623 for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2023-Q2RestatedAnnual report
「Against this backdrop, the Group advanced research and development with the aim of commercialising its proprietary regenerative cell therapy SB623, primarily targeting central nervous system disorders with high unmet medical needs.」
The policy of advancing research and development toward the commercialization of SB623, primarily targeting central nervous system diseases with high unmet medical needs, has been reaffirmed. - FY2023-Q1RestatedAnnual report
「We advanced research and development aimed at commercializing SB623, our group’s proprietary regenerative cell therapy, primarily targeting central nervous system diseases with high unmet medical needs.」
The policy of seeking to provide value through regenerative medicine for central nervous system diseases with high unmet medical needs has been reaffirmed. - FY2020RestatedAnnual report
「We have adopted as our corporate mission the provision of value to patients and other stakeholders through the development of regenerative medicine, are pursuing the goal of becoming a global leader in the regenerative medicine field, and are conducting research and development of regenerative cell medicines.」
The policy of providing value to stakeholders through regenerative medicine, aspiring to global leadership, and improving patients’ QOL through early commercialization has been reaffirmed. - FY2019RestatedAnnual report
「Our group, which conducts research and development and manufacturing of regenerative cell medicines, has adopted the corporate philosophy, “Through the development of regenerative medicine, we will provide value to patients and other stakeholders.” We are pursuing the goal of becoming a global leader in the regenerative medicine field and conducting research and development of regenerative cell medicines.」
The corporate philosophy of providing value to stakeholders through regenerative medicine, aspiring to global leadership, achieving early commercialization, and improving QOL has been reaffirmed. - FY2018ReframedAnnual report
「Our group, which conducts research and development and manufacturing of regenerative medicine products, has adopted the corporate philosophy, “Through the development of regenerative medicine, we will provide value to patients and other stakeholders.” We are pursuing the goal of becoming a global leader in the regenerative medicine field and conducting research and development of regenerative medicine products. By bringing our products to market at an early stage, we will contribute to improving patients’ QOL (Quality of Life) as soon as possible and help create a richer, happier society.」
In addition to the previous emphasis on addressing unmet medical needs, the company is highlighting its goals of becoming a global leader in regenerative medicine, achieving early commercialization, and improving patients’ QOL as its corporate philosophy and policy. - FY2017First statedAnnual report
「Through the development of regenerative cell therapies, we address unmet medical needs (medical needs for which no effective treatment is yet available) and create value for stakeholders.」
The company has established as its corporate mission the fulfillment of unmet medical needs through regenerative cell therapies and the creation of value for stakeholders.